Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Jim Wassil also recently made the following trade(s):
- On Monday, February 3rd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.22, for a total value of $689,760.00.
- On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $83.66, for a total value of $669,280.00.
Vaxcyte Stock Performance
Shares of NASDAQ PCVX traded down $3.63 during midday trading on Friday, hitting $71.18. 1,355,596 shares of the stock traded hands, compared to its average volume of 1,195,973. The firm has a 50-day moving average of $83.33 and a two-hundred day moving average of $94.51. The firm has a market capitalization of $9.17 billion, a P/E ratio of -15.47 and a beta of 1.02. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. Equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
PCVX has been the topic of several analyst reports. The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte currently has a consensus rating of "Buy" and an average target price of $147.50.
Check Out Our Latest Research Report on PCVX
Hedge Funds Weigh In On Vaxcyte
Hedge funds and other institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in shares of Vaxcyte by 5.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company's stock worth $252,000 after purchasing an additional 110 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in shares of Vaxcyte by 60.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 64,664 shares of the company's stock worth $7,389,000 after purchasing an additional 24,322 shares in the last quarter. Amalgamated Bank increased its stake in shares of Vaxcyte by 8.6% in the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company's stock worth $466,000 after purchasing an additional 322 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Vaxcyte by 186.2% in the 3rd quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after purchasing an additional 34,287 shares in the last quarter. Finally, Atria Investments Inc purchased a new stake in shares of Vaxcyte in the 3rd quarter worth $286,000. 96.78% of the stock is owned by institutional investors.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
